What is the recommended inpatient treatment regimen for community-acquired pneumonia?

Inpatient Treatment of Community-Acquired Pneumonia

For non-ICU hospitalized patients with community-acquired pneumonia, administer a β-lactam (ceftriaxone, cefotaxime, ampicillin-sulbactam, or ceftaroline) combined with azithromycin as the preferred regimen, or use respiratory fluoroquinolone monotherapy (levofloxacin or moxifloxacin) as an equivalent alternative. 1, 2

Non-ICU Inpatient Regimens

Preferred Combination Therapy

• β-lactam plus macrolide is the standard approach, with strong evidence supporting improved clinical outcomes 1, 2
• Specific β-lactam options include:
  • Ceftriaxone 1–2 g IV daily 1, 2
  • Cefotaxime 1–2 g IV every 8 hours 1, 2
  • Ampicillin-sulbactam 1.5–3 g IV every 6 hours 1, 2
  • Ceftaroline (for broader coverage) 1, 2
• Azithromycin is the preferred macrolide over other macrolides due to better pharmacokinetics and once-daily dosing 1, 2

Alternative Monotherapy

• Respiratory fluoroquinolone monotherapy achieves comparable clinical outcomes to combination therapy in meta-analyses 1, 2
• Specific fluoroquinolone options:
  • Levofloxacin 750 mg IV/PO daily 1, 2
  • Moxifloxacin 400 mg IV/PO daily 1, 2
• Fluoroquinolones have fewer treatment discontinuations than combination regimens, though observational data suggest combination therapy may confer a mortality benefit 2

When Both Macrolides and Fluoroquinolones Are Contraindicated

• Use β-lactam plus doxycycline 100 mg IV/PO twice daily as an alternative 2

ICU-Level Severe Pneumonia

For critically ill patients requiring ICU admission, combination therapy with a β-lactam plus azithromycin is strongly recommended and reduces mortality by approximately 18% relative risk (≈3% absolute reduction) compared with non-macrolide regimens. 1, 2

Standard ICU Regimens

• β-lactam (ceftriaxone, cefotaxime, or ampicillin-sulbactam) plus azithromycin is the preferred regimen 1, 2
• β-lactam plus respiratory fluoroquinolone (levofloxacin 750 mg or moxifloxacin) is an acceptable alternative 1, 2
• Macrolide-containing regimens demonstrate superior mortality outcomes in observational studies of ~10,000 critically ill patients 1, 2

Special Pathogen Coverage in ICU Patients

Pseudomonas aeruginosa Risk Factors

Add antipseudomonal coverage when any of the following are present: 1, 2

• Structural lung disease (bronchiectasis, cystic fibrosis)
• Recent broad-spectrum antibiotics within 90 days
• Recent hospitalization with parenteral antibiotics ≤90 days
• Prior Pseudomonas isolation

Antipseudomonal regimen: 1, 2

• Antipseudomonal β-lactam (piperacillin-tazobactam 4.5 g IV every 6 hours, cefepime 2 g IV every 8 hours, imipenem 500 mg IV every 6 hours, or meropenem 1 g IV every 8 hours)
• PLUS either:
  • Ciprofloxacin 400 mg IV every 8 hours or levofloxacin 750 mg IV daily, OR
  • Aminoglycoside (gentamicin or tobramycin) plus azithromycin, OR
  • Aminoglycoside plus antipneumococcal fluoroquinolone

For penicillin-allergic patients with Pseudomonas risk: substitute aztreonam 2 g IV every 8 hours for the β-lactam 1, 2

MRSA Risk Factors

Add MRSA coverage when any of the following are present: 1, 2

• Prior MRSA infection or colonization
• Intravenous drug use
• Recent influenza infection
• Known MRSA nasal colonization

MRSA regimen: 1, 2

• Vancomycin 15–20 mg/kg IV every 8–12 hours (target trough 15–20 mcg/mL), OR
• Linezolid 600 mg IV every 12 hours

Critical Timing Considerations

Administer the first antibiotic dose in the emergency department before hospital admission; delays beyond 4–8 hours are associated with increased mortality. 1, 2

Treatment Duration and Clinical Stability

Treat for a minimum of 5 days once the patient has been afebrile for 48–72 hours and exhibits no more than one sign of clinical instability. 1, 2, 3

Signs of Clinical Instability

Any of the following indicate ongoing instability: 1, 2

• Heart rate >100 beats/min
• Respiratory rate >24 breaths/min
• Systolic blood pressure <90 mmHg
• Oxygen saturation <90% or PaO₂ <60 mmHg on room air
• Inability to maintain oral intake
• Altered mental status

When to Extend Beyond 5 Days

Prolong therapy only when: 1, 2

• Initial regimen was inactive against the identified pathogen
• Extrapulmonary complications develop (meningitis, endocarditis, empyema, lung abscess)
• Documented infection with Legionella, Staphylococcus aureus, or gram-negative bacilli

Recent evidence supports 3-day treatment for patients achieving clinical stability by day 3, particularly younger patients with fewer comorbidities treated with amoxicillin or injectable β-lactams. 3

IV-to-Oral Switch and Discharge

Switch from IV to oral antibiotics once the patient is hemodynamically stable, clinically improving, able to ingest medication, and has a functional gastrointestinal tract—typically after 2–3 days of IV therapy. 1, 2

Discharge immediately after the IV-to-oral switch if the patient remains clinically stable, without requiring additional observation. 1, 2

Oral Step-Down Options

• If started on β-lactam/macrolide: switch to amoxicillin 1 g PO three times daily plus azithromycin 500 mg PO daily (or doxycycline 100 mg PO twice daily) 2
• If started on fluoroquinolone: continue levofloxacin 750 mg PO daily or moxifloxacin 400 mg PO daily 2

Monitoring and Reassessment

Reassess daily the need for continued antibiotics; if pulmonary infiltrates resolve rapidly with diuresis alone (within 24–48 hours), consider stopping antibiotics when true pneumonia is unlikely. 1

This scenario is particularly relevant in patients with congestive heart failure where lack of fever, leukocytosis, and purulent sputum should raise suspicion for pure pulmonary edema rather than pneumonia. 1

Critical Pitfalls to Avoid

• Do not use macrolide monotherapy in regions where pneumococcal macrolide resistance exceeds 25%, as efficacy is markedly reduced 1, 2
• Do not add MRSA or Pseudomonas coverage without documented risk factors, as this leads to unnecessary broad-spectrum exposure and promotes resistance 1, 2
• Do not continue antibiotics beyond 5 days in clinically stable patients to prevent resistance development and adverse events 1, 2
• Do not delay ICU admission for patients meeting severe CAP criteria (requiring vasopressors or mechanical ventilation), as delays increase mortality 1, 2
• Avoid reflexively treating all patients with radiographic infiltrates as pneumonia; consider alternative diagnoses such as pulmonary edema, pulmonary embolism, or malignancy, especially when fever and leukocytosis are absent 1, 4
• Do not use β-lactam monotherapy for hospitalized patients, as this is associated with increased re-admission rates and inferior outcomes compared to combination therapy 5